QIAGEN N.V., (NYSE: QGEN) disclosed that it has finalized a U.S. government agreed to provide QIAcuity digital PCR system to public health laboratories across the country to observe the spread of the COVID-19 pandemic by testing wastewater for the presence of SARS-CoV-2 pathogens.
More than 70% of all U.S. states now have at least one laboratory with a QIAcuity system for wastewater surveillance, whether public or private. The ultra-sensitive digital PCR platform has established new benchmarks for producing quick findings in two hours rather than the six hours needed by competitors’ proprietary nanoplate-based techniques.
Furthermore, as part of a multi-million-dollar deal with the US National Institutes of Health (NIH) to deliver COVID-19 instruments and consumables until the end of 2021, QIAGEN has supplied more than 35 QIAcuity systems to state and local health laboratories. This agreement with QIAGEN has given public health laboratories quick and easy access to extraction equipment and supplies, allowing them to conduct surveillance as well as wastewater testing in support of the pandemic response.
In addition, QIAcuity is a perfect solution for testing for SARS-CoV-2 infections in sewage specimens, and QIAGEN is ready to assist public health labs in the United States and around the world in generating critical information to supplement epidemiological data. Genetic surveillance is proven to be a valuable tool these days, and it will continue to be so in the future. As COVID-19 becomes endemic, the focus of testing will move away from detecting viruses and toward tracking the spread of the virus illnesses.